Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Staffaroni AM, Bajorek L, Casaletto KB, Cobigo Y, Goh SM, Wolf A, Heuer HW, Elahi FM, Ljubenkov PA, Dever R, Kornak J, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber D, Caso C, Coppola G, Dheel C, Dickerson BC, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fields JA, Fishman A, Fong J, Foroud T, Forsberg LK, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY, Huey ED, Irwin DJ, Jones DT, Jones L, Kantarci K, Karydas A, Kaufer DI, Kerwin DR, Knopman DS, Kraft R, Kremers WK, Kukull WA, Litvan I, Lucente D, Lungu C, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley E, Mendez MF, Miller BL, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wang P, Wong B, Wszolek Z, Boxer AL, Boeve BF, Kramer JH, Rosen HJ; ARTFL/LEFFTDS consortium.

Alzheimers Dement. 2020 Jan;16(1):11-21. doi: 10.1016/j.jalz.2019.01.012.

PMID:
31914230
2.

Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration.

Casaletto KB, Staffaroni AM, Wolf A, Appleby B, Brushaber D, Coppola G, Dickerson B, Domoto-Reilly K, Elahi FM, Fields J, Fong JC, Forsberg L, Ghoshal N, Graff-Radford N, Grossman M, Heuer HW, Hsiung GY, Huey ED, Irwin D, Kantarci K, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Litvan I, Mackenzie IR, Mendez M, Miller B, Rademakers R, Ramos EM, Rascovsky K, Roberson ED, Syrjanen JA, Tartaglia MC, Weintraub S, Boeve B, Boxer AL, Rosen H, Yaffe K; ARTFL/LEFFTDS Study.

Alzheimers Dement. 2020 Jan;16(1):91-105. doi: 10.1002/alz.12001.

PMID:
31914227
3.

Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort.

Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber DE, Caso C, Coppola G, Dickerson B, Dickinson S, Domoto-Reilly K, Faber K, Ferrall J, Fields J, Fishman A, Fong J, Foroud T, Forsberg LK, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY, Huey E, Irwin D, Jones D, Kantarci K, Karydas A, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Kraft R, Kremers WK, Kukull W, Litvan I, Ljubenkov P, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis S, McKinley E, Mendez MF, Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Roberson ED, Rogalski E, Sengdy P, Shaw L, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski J, Weintraub S, Wong B, Wszolek Z, Boeve BF, Rosen HJ, Boxer AL; ARTFL and LEFFTDS consortia.

Alzheimers Dement. 2020 Jan;16(1):60-70. doi: 10.1002/alz.12046.

PMID:
31914226
4.

Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.

Miyagawa T, Brushaber D, Syrjanen J, Kremers W, Fields J, Forsberg LK, Heuer HW, Knopman D, Kornak J, Boxer A, Rosen HJ, Boeve BF, Appleby B, Bordelon Y, Bove J, Brannelly P, Caso C, Coppola G, Dever R, Dheel C, Dickerson B, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrell J, Fishman A, Fong J, Foroud T, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman JS, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung R, Huey E, Irwin D, Jones D, Jones L, Kantarci K, Karydas A, Kaufer D, Kerwin D, Kraft R, Kramer J, Kukull W, Litvan I, Lucente D, Lungu C, Mackenzie I, Maldonado M, Manoochehri M, McGinnis S, McKinley E, Mendez MF, Miller B, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin K, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw L, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Wang P, Weintraub S, Wong B, Wszolek Z.

Alzheimers Dement. 2020 Jan;16(1):106-117. doi: 10.1002/alz.12033.

PMID:
31914218
5.

Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases.

Ramos EM, Dokuru DR, Van Berlo V, Wojta K, Wang Q, Huang AY, Deverasetty S, Qin Y, van Blitterswijk M, Jackson J, Appleby B, Bordelon Y, Brannelly P, Brushaber DE, Dickerson B, Dickinson S, Domoto-Reilly K, Faber K, Fields J, Fong J, Foroud T, Forsberg LK, Gavrilova R, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Heuer HW, Hsiung GR, Huey E, Irwin D, Kantarci K, Karydas A, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Kremers W, Kukull W, Litvan I, Ljubenkov P, Lungu C, Mackenzie I, Mendez MF, Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Shaw L, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wong B, Wszolek Z, Rademakers R, Boeve BF, Rosen HJ, Boxer AL; ARTFL/LEFFTDS consortium, Coppola G.

Alzheimers Dement. 2020 Jan;16(1):118-130. doi: 10.1002/alz.12011.

PMID:
31914217
6.

Unique white matter structural connectivity in early-stage, drug-naive Parkinson disease.

Mishra VR, Sreenivasan KR, Yang Z, Zhuang X, Cordes D, Mari Z, Litvan I, Fernandez HH, Eidelberg D, Ritter A, Cummings JL, Walsh RR.

Neurology. 2019 Dec 27. pii: 10.1212/WNL.0000000000008867. doi: 10.1212/WNL.0000000000008867. [Epub ahead of print]

PMID:
31882528
7.

Nonlinear Z-score modeling for improved detection of cognitive abnormality.

Kornak J, Fields J, Kremers W, Farmer S, Heuer HW, Forsberg L, Brushaber D, Rindels A, Dodge H, Weintraub S, Besser L, Appleby B, Bordelon Y, Bove J, Brannelly P, Caso C, Coppola G, Dever R, Dheel C, Dickerson B, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fishman A, Fong J, Foroud T, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant IM, Grossman M, Haley D, Hsiao J, Hsiung R, Huey ED, Irwin D, Jones D, Jones L, Kantarci K, Karydas A, Kaufer D, Kerwin D, Knopman D, Kraft R, Kramer J, Kukull W, Lapid M, Litvan I, Ljubenkov P, Lucente D, Lungu C, Mackenzie I, Maldonado M, Manoochehri M, McGinnis S, McKinley E, Mendez M, Miller B, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin K, Rascovsky K, Roberson ED, Rogalski-Miller E, Sengdy P, Shaw L, Staffaroni AM, Sutherland M, Syrjanen J, Tartaglia C, Tatton N, Taylor J, Toga A, Trojanowski J, Wang P, Wong B, Wszolek Z, Boeve B, Boxer A, Rosen H; ARTFL/LEFFTDS Consortium.

Alzheimers Dement (Amst). 2019 Dec 5;11:797-808. doi: 10.1016/j.dadm.2019.08.003. eCollection 2019 Dec.

8.

Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.

Olney NT, Ong E, Goh SM, Bajorek L, Dever R, Staffaroni AM, Cobigo Y, Bock M, Chiang K, Ljubenkov P, Kornak J, Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber D, Caso C, Coppola G, Dickerson BC, Dickinson S, Domoto-Reilly K, Faber K, Ferrall J, Fields J, Fishman A, Fong J, Foroud T, Forsberg LK, Gearhart DJ, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford NR, Grant I, Grossman M, Haley D, Hsiung G, Huey ED, Irwin DJ, Jones DT, Kantarci K, Karydas AM, Kaufer D, Kerwin D, Knopman DS, Kramer JH, Kraft R, Kremers W, Kukull W, Lapid MI, Litvan I, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley EC, Mendez MF, Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wong B, Wszolek Z, Boxer AL, Boeve BF, Rosen HJ; ARTFL and LEFFTDS consortia.

Alzheimers Dement. 2020 Jan;16(1):49-59. doi: 10.1016/j.jalz.2019.08.196. Epub 2020 Jan 6.

9.

Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

Saijo E, Metrick MA 2nd, Koga S, Parchi P, Litvan I, Spina S, Boxer A, Rojas JC, Galasko D, Kraus A, Rossi M, Newell K, Zanusso G, Grinberg LT, Seeley WW, Ghetti B, Dickson DW, Caughey B.

Acta Neuropathol. 2020 Jan;139(1):79-81. doi: 10.1007/s00401-019-02092-y.

PMID:
31748840
10.

Abnormal distraction and load-specific connectivity during working memory in cognitively normal Parkinson's disease.

Harrington DL, Shen Q, Vincent Filoteo J, Litvan I, Huang M, Castillo GN, Lee RR, Bayram E.

Hum Brain Mapp. 2019 Nov 18. doi: 10.1002/hbm.24868. [Epub ahead of print]

PMID:
31737972
11.

Frontrunner in Translation: Progressive Supranuclear Palsy.

Shoeibi A, Olfati N, Litvan I.

Front Neurol. 2019 Oct 22;10:1125. doi: 10.3389/fneur.2019.01125. eCollection 2019. Review.

12.

Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Shoeibi A, Litvan I, Juncos JL, Bordelon Y, Riley D, Standaert D, Reich SG, Shprecher D, Hall D, Marras C, Kluger B, Olfati N, Jankovic J.

Parkinsonism Relat Disord. 2019 Dec;69:34-39. doi: 10.1016/j.parkreldis.2019.10.012. Epub 2019 Oct 14.

PMID:
31665686
13.

4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

Saijo E, Metrick MA 2nd, Koga S, Parchi P, Litvan I, Spina S, Boxer A, Rojas JC, Galasko D, Kraus A, Rossi M, Newell K, Zanusso G, Grinberg LT, Seeley WW, Ghetti B, Dickson DW, Caughey B.

Acta Neuropathol. 2020 Jan;139(1):63-77. doi: 10.1007/s00401-019-02080-2. Epub 2019 Oct 16. Erratum in: Acta Neuropathol. 2019 Nov 20;:.

PMID:
31616982
14.

Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy.

Sakae N, Josephs KA, Litvan I, Murray ME, Duara R, Uitti RJ, Wszolek ZK, Graff-Radford NR, Dickson DW.

Mov Disord. 2019 Nov;34(11):1655-1662. doi: 10.1002/mds.27816. Epub 2019 Aug 21.

15.

Hypertension and progressive supranuclear palsy.

Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J; ENGENE PSP study.

Parkinsonism Relat Disord. 2019 Sep;66:166-170. doi: 10.1016/j.parkreldis.2019.07.036. Epub 2019 Aug 3.

PMID:
31420308
16.

Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management.

Goud KY, Moonla C, Mishra RK, Yu C, Narayan R, Litvan I, Wang J.

ACS Sens. 2019 Aug 23;4(8):2196-2204. doi: 10.1021/acssensors.9b01127. Epub 2019 Aug 12.

PMID:
31403773
17.

Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome.

Sakae N, Josephs KA, Litvan I, Murray ME, Duara R, Uitti RJ, Wszolek ZK, van Gerpen J, Graff-Radford NR, Dickson DW.

Alzheimers Dement. 2019 Sep;15(9):1218-1228. doi: 10.1016/j.jalz.2019.04.011. Epub 2019 Aug 6.

PMID:
31399334
18.

Occupation and Parkinson disease in the Women's Health Initiative Observational Study.

Burstyn I, LaCroix AZ, Litvan I, Wallace RB, Checkoway H.

Am J Ind Med. 2019 Sep;62(9):766-776. doi: 10.1002/ajim.23022. Epub 2019 Jul 22.

PMID:
31328814
19.

Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Faust-Socher A, Duff-Canning S, Grabovsky A, Armstrong MJ, Rothberg B, Eslinger PJ, Meaney CA, Schneider RB, Tang-Wai DF, Fox SH, Zadikoff C, Kennedy N, Chou KL, Persad C, Litvan I, Mast BT, Gerstenecker AT, Weintraub S, Reginold W, Marras C.

Dement Geriatr Cogn Disord. 2019;47(4-6):187-197. doi: 10.1159/000496454. Epub 2019 Jul 17.

PMID:
31315127
20.

Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.

Shoeibi A, Litvan I, Tolosa E, Ser TD, Lee E; TAUROS Investigators.

Parkinsonism Relat Disord. 2019 Sep;66:87-93. doi: 10.1016/j.parkreldis.2019.07.010. Epub 2019 Jul 9.

PMID:
31307919
21.

Factor Analysis of the Apathy Scale in Parkinson's Disease.

Lopez FV, Eglit GML, Schiehser DM, Pirogovsky-Turk E, Litvan I, Lessig S, Filoteo JV.

Mov Disord Clin Pract. 2019 Apr 30;6(5):379-386. doi: 10.1002/mdc3.12767. eCollection 2019 Jun.

PMID:
31286007
22.

Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.

Staffaroni AM, Cobigo Y, Goh SM, Kornak J, Bajorek L, Chiang K, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber D, Caso C, Coppola G, Dever R, Dheel C, Dickerson BC, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fields JA, Fishman A, Fong J, Foroud T, Forsberg LK, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Heuer HW, Hsiung GY, Huey ED, Irwin DJ, Jones DT, Jones L, Kantarci K, Karydas A, Kaufer DI, Kerwin DR, Knopman DS, Kraft R, Kramer JH, Kremers WK, Kukull WA, Litvan I, Ljubenkov PA, Lucente D, Lungu C, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley E, Mendez MF, Miller BL, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wang P, Wong B, Wszolek Z, Boxer AL, Boeve BF, Rosen HJ; ARTFL/LEFFTDS consortium.

Alzheimers Dement. 2020 Jan;16(1):37-48. doi: 10.1016/j.jalz.2019.04.007. Epub 2020 Jan 6.

23.

The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners.

Hicks A, Phillips K, Siwik C, Salmon P, Litvan I, Jablonski ME, Filoteo JV, Kayser K, Sephton SE.

Qual Life Res. 2019 Oct;28(10):2705-2716. doi: 10.1007/s11136-019-02217-6. Epub 2019 Jun 14.

PMID:
31201728
24.

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T.

Lancet Neurol. 2019 Jun;18(6):549-558. doi: 10.1016/S1474-4422(19)30139-5.

PMID:
31122495
25.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Aug;34(8):1228-1232. doi: 10.1002/mds.27666. Epub 2019 Mar 18.

26.

Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.

Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B.

Alzheimers Res Ther. 2019 Mar 13;11(1):23. doi: 10.1186/s13195-019-0476-1.

27.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926. Review.

28.

End of life planning in parkinsonian diseases.

Gillard DM, Proudfoot JA, Simões RM, Litvan I.

Parkinsonism Relat Disord. 2019 May;62:73-78. doi: 10.1016/j.parkreldis.2019.01.026. Epub 2019 Jan 30.

PMID:
30718221
29.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2019 Mar;34(3):430-435. doi: 10.1002/mds.27617. Epub 2019 Jan 17.

PMID:
30653248
30.

The virtual reality of Parkinson's disease freezing of gait: A systematic review.

Bluett B, Bayram E, Litvan I.

Parkinsonism Relat Disord. 2019 Apr;61:26-33. doi: 10.1016/j.parkreldis.2018.11.013. Epub 2018 Nov 15. Review.

PMID:
30470656
31.

Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers.

Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA.

J Alzheimers Dis. 2018;66(4):1539-1548. doi: 10.3233/JAD-180789.

PMID:
30412501
32.

Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease.

Harrington DL, Shen Q, Theilmann RJ, Castillo GN, Litvan I, Filoteo JV, Huang M, Lee RR.

Front Aging Neurosci. 2018 Oct 23;10:331. doi: 10.3389/fnagi.2018.00331. eCollection 2018.

33.

Progress in the treatment of Parkinson-Plus syndromes.

Olfati N, Shoeibi A, Litvan I.

Parkinsonism Relat Disord. 2019 Feb;59:101-110. doi: 10.1016/j.parkreldis.2018.10.006. Epub 2018 Oct 3.

PMID:
30314846
34.

Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy.

Shoeibi A, Litvan I.

Mov Disord Clin Pract. 2018 Jan-Feb;5(1):99-100. doi: 10.1002/mdc3.12562. Epub 2017 Oct 23. No abstract available.

35.

Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.

Moreno GM, Gandhi R, Lessig SL, Wright B, Litvan I, Nahab FB.

Neurology. 2018 Oct 23;91(17):797-799. doi: 10.1212/WNL.0000000000006396. Epub 2018 Sep 26. No abstract available.

36.

Does the Geriatric Depression Scale measure depression in Parkinson's disease?

Lopez FV, Split M, Filoteo JV, Litvan I, Moore RC, Pirogovsky-Turk E, Liu L, Lessig S, Schiehser DM.

Int J Geriatr Psychiatry. 2018 Dec;33(12):1662-1670. doi: 10.1002/gps.4970. Epub 2018 Sep 25.

37.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14. Review.

38.

Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease.

Bluett B, Banks S, Cordes D, Bayram E, Mishra V, Cummings J, Litvan I.

Alzheimers Dement (N Y). 2018 Jun 13;4:387-394. doi: 10.1016/j.trci.2018.04.010. eCollection 2018.

39.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
40.

Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D.

Mov Disord. 2018 Oct;33(10):1601-1608. doi: 10.1002/mds.27362. Epub 2018 Aug 25.

PMID:
30145797
41.

Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress.

Yuan SH, Hiramatsu N, Liu Q, Sun XV, Lenh D, Chan P, Chiang K, Koo EH, Kao AW, Litvan I, Lin JH.

Hum Mol Genet. 2018 Nov 15;27(22):3951-3963. doi: 10.1093/hmg/ddy297.

42.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

43.

Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.

44.

Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans.

Kelley KD, Checkoway H, Hall DA, Reich SG, Cunningham C, Litvan I.

Front Neurol. 2018 Jun 20;9:474. doi: 10.3389/fneur.2018.00474. eCollection 2018.

45.

Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.

Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, Graff-Radford N, Ahlskog JE, Uitti RJ, van Gerpen JA, Boeve BF, Parks A, Ross OA, Dickson DW.

Acta Neuropathol. 2018 Sep;136(3):389-404. doi: 10.1007/s00401-018-1878-z. Epub 2018 Jun 20.

46.

Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.

Shoeibi A, Olfati N, Litvan I.

Expert Opin Investig Drugs. 2018 Apr;27(4):349-361. doi: 10.1080/13543784.2018.1460356. Epub 2018 Apr 9. Review.

47.

Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.

Litvan I, Kieburtz K, Tröster AI, Aarsland D.

Mov Disord. 2018 Apr;33(4):520-527. doi: 10.1002/mds.27345. Epub 2018 Mar 24. Review.

PMID:
29573469
48.

Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.

Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP.

Mov Disord. 2018 Apr;33(4):503-510. doi: 10.1002/mds.27323. Epub 2018 Feb 28. Review.

PMID:
29488270
49.

Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, Shprecher DR, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I; ENGENE-PSP Study.

Mov Disord. 2018 Mar;33(3):468-472. doi: 10.1002/mds.27336. Epub 2018 Feb 20.

50.

At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.

Weintraub D, Hamilton JL, Eberling J, Litvan I.

Mov Disord. 2018 Apr;33(4):501-502. doi: 10.1002/mds.27310. Epub 2018 Feb 8. No abstract available.

PMID:
29418018

Supplemental Content

Loading ...
Support Center